The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Heimdal,
Its been "clearly stated" on numerous occasions about other dates, non of which have ever been met, so you cannot but forgive shareholders doubts after so many times being let down. Especially as we get closer to the goal which should, according to previous announcements, have happened years ago.
One can only be positive for so long before one realises what a complete bunch of clowns have been running the company since 2016. The latest joke of course being the issuance of 2.5mill shares as payment to a 3rd party for being a strategic adviser to the DLI app. Surely if the app were that good, why would they need a consultant to advise on which insurance companies to approach? Mind you, I'm pretty sure most insurance companies will not be interested since they will be developing their own models / algorithms and keep it all in-house ?
Anyroadup, there is still another 8 working days left to meet their latest milestone date, so we wait and see in complete faith and anticipation....and pigs might fly......lol.
On May 11 RPG clearly stated that; “The Group remains on target to submit the study to the US Food and Drug Administration (“FDA”) at the end of June 2021 depending on the results of the study.” End of June... Heimdal
https://www.charltonslaw.com/hong-kong-law/statutory-regime-for-the-disclosure-of-price-sensitive-information-implications-for-listed-companies-and-their-directors/#3 dougie if you read through this it sets out the disclosure regime in some detail.i don't know if there is anything later ,but the principles are fairly clear."as soon as reasonably practical"doesn't mean immediately ,but the provisos to allow time to elapse(e.g. investigation)wouldn't suggest regent could postpone for very long informing the market of the results,once known.obviouslywe don't know exactly what is going on and what state of knowledge the company has,but its hard to see how they could put off advising the market virtually as soon as they have been informed of the results.this assumes the information is market sensitive in accordance with the definition,but it is impossible really to imagine it could not be.how seriously the statutory obligations are taken and what action if any is likely to follow if a company drags its feet is of course open to speculation. i cannot see any reason or excuse to delay ,but it may just be that they haven't finished the process yet and as bignose suggests, it is all just taking longer than suggested as that is the usual case with regent.
Is there a reason the company would hold of until the last few days to release the results ? Or would they be expected to announce them even if they are ahead of schedule ? I will hold of my concern until the end of the month when they said it would be done .
fair enough bignose.you will probably be proved right and you certainly have the weight of history on your side.
I will be highly surprised if otherwise.
The.Italian.
I don’t think anyone is expecting them to meet their own schedule since they never have. I would suspect that since it took 12 months longer to complete the phase II trials, which themselves were delayed by 6 months, we won’t see any results till q3/q4. Just being realistic on their own ever changing timelines.
at the risk of stating the obvious, there are only 9 trading days left until the end of june .so topline results and update on FDA submission timeframe is drawing to a close.fingers crossed.